All the $SPCX coverage is live on DeepView right now. News, updates, stock info if you want to see what’s going on with SpaceX today, it’s all there. Go check it out!!!!!!

7/ The platform also includes powerful tools for deeper analysis. Features include: ➜AI-powered screeners ➜DeepView analysis ➜Support & resistance mapping ➜Risk assessments Users can identify undervalued assets, unusual options activity, & signs of institutional money flow.

🇬🇧 The upcoming British Burn Association Annual Meeting will take place June 17-19, 2026 at the Nottingham Trent University in Nottingham, England. Come see us & our DeepView AI® System at stand #22! Read the full release investors.spectral-ai.com/ne…

Deepview is more accurate. JUST SAYING

Everyone should be using this the AI DAILY BRIEF on deepview is a game changer $NVDA $SPY $AAPL $GOOGL $AMD

New Options chain on deepview go try it out $NVDA $SPY $GOOGL

DeepView just added a new Short Interest module that lets you see the short interest of any stock. Give it a try and let me know what you think. $SPY $NVDA $GOOGL $AAPL

We’re thrilled to see our DeepView AI® System being discussed by surgeons in Egypt today. 🙌 Consultant Burn Surgeon Mr Christopher Lewis has given a presentation on Artificial Intelligence in burn surgery. #DeepView #SpectralAI #MDAI

🎉 A milestone moment in Times Square! We were honored to see Spectral AI featured on the Nasdaq tower in celebration of our FDA De Novo clearance for the DeepView® System for Burn Indication. #MDAI #SpectralAI #Nasdaq #TimesSquare #HealthcareInnovation #AIinMedicalDevices

El 26 de mayo la FDA dio clasificación De Novo al sistema DeepView de Spectral AI para quemaduras. Es un buen ejemplo de la IA que de verdad cambia la medicina: no un chatbot dando opiniones, sino una máquina que mira una herida en 0.2 segundos, procesa la imagen en unos 20 segundos y ayuda a decidir si esa piel probablemente no sanará en 21 días y necesita intervención. Eso puede ahorrar sufrimiento, cirugías tardías y dinero. También muestra algo incómodo para Europa. La innovación médica no nace de comités que escriben reglamentos perfectos. Nace cuando emprendedores, clínicos, capital, datos y reguladores se organizan para probar, medir y autorizar. BARDA apoyó el proyecto, la FDA abrió una vía, y una empresa pequeña llegó al mercado. Esa es la alianza correcta entre Estado y mercado: el Estado no sustituye al empresario, pero tampoco bloquea durante años una tecnología que puede salvar tejido y vidas. En medicina la prudencia importa. Pero la parálisis también mata.

$MDAI- Commercial distribution of the company's DeepView System for burn patients now authorized by FDA

Spectral AI receives FDA De Novo Clearance for DeepView Burn *$MDAI may now begin commercial distribution in the US finance.yahoo.com/sectors/he…

@grok Spectral AI $MDAI got FDA De Novo clearance for Deepview AI for burn care settings and emergency departments on May 21st. How long will the backend work take before it can start to contribute to revenue? I've read hospitals and government pre-commitments are lined up and ready. How much revenue would you estimate if you had to these early orders will bring in in 2026 and 2027?

🚨 $MDAI — THE WAIT IS OVER! ⏳➡️✅ I fucking LOVE this! FDA **GRANTED** De Novo clearance for DeepView AI® System (DEN250028) on May 21, 2026. Proof: accessdata.fda.gov/scripts/c… All it takes is a new FDA under President @realDonaldTrump to cut the red tape and get American AI-medtech winning again. Burn victims and patients win big! Short interest ~9% of float (1.99M shares) low float = this thing is primed. Biggest overhang crushed. US hospital sales in burn centers & EDs unlocked for H2 2026 ramp with BARDA funding. @Spectral_MDAI — drop the official PR ASAP and let’s run! Monday gap incoming? Tagging the real $MDAI crew who’ve been in the trenches: @capybaraReform @aipatternlab @hassytrades @BawzRs @HiddenTraderX07 @NikolaRolotrade @modern_rock @TigerLineTrades @Angel_Perseo_ @Sir_Kory @Stock_Pursuit @deadwoodagenda #MDAI #DeepView #FDAcleared #MedTech #AIinMedicine #TrumpFDA #ShortSqueezePotential #Stocks #MDAIW $MDAI $MDAIW

$MDAI Awaiting Grant of DeepView De Novo Request #AI #diagnostics buff.ly/bqjjoEB

🔥 $MDAI Posible filtración de aprobación FDA para Spectral antes de comunicado oficial. La web de la FDA ya muestra “Decision Granted” para DeepView AI. El gráfico lleva años comprimiendo entre 1$ y 3$. 👀 Nivel que cambia el juego: ➡️ ruptura de 3.15$ 🎯 4.6$ 🎯 10$

For penny lovers... $MDAI DeepView AI, the AI-powered imaging system for burn wound assessment, expects a positive FDA decision by end of Q2 2026. In a 15-month validation study, it achieved 92% accuracy in predicting wound healing vs. 50-75% for expert clinical judgment (which typically requires 3-4 weeks of observation). Catalysts: • Q2: FDA decision delivery of handheld prototype to MTEC (DoD) • H2: Unlock ~$60M additional non-dilutive BARDA funding first U.S. commercial sales • UKCA update enabling initial sales in UK, Australia & GCC countries BARDA has already committed $86.6M (including $31.7M in March 2026), strong U.S. government backing with non-dilutive capital. Spectral AI is the first-mover in AI burn imaging and is developing a portable handheld version for military & emergency use. High risk/high reward medtech play. Just a new idea not hyped yet.. 😉 For larger, more structured companies (mid and large-caps) or portfolio examples, you can follow me on Substack ☺️ DYOR. NFA.

Follow-up: Spectral AI $MDAI in the last conference call management sounds confident in the FDA approval clearance decision by the end of Q2 this year. They just got $31.7 mil in funding in March. It looks like based on the timeframe to me it could be later by Sept. It could potentially be longer as my research shows AI algorithm involved medical devices can take longer. Of course, nothing is certain and it may not get approved. Still, we are approaching the end of the time window. FDA approval would be a huge catalyst for this small company. This will be a big breakthrough in wound care diagnostics if approved. Based on the available info it is far superior at diagnosing burn wounds quickly. It looks like everything is on-track and they are hiring sales teams. Deepview is being evaluated at facilities in the U.K. currently. Disclosure: I'm long MDAI stock

🚨 $MDAI (Spectral AI) Q1 2026 Earnings BARDA-funded development progress continues amid revenue transition 👀 📊 KEY METRICS (Q1 2026) 🔹 R&D Revenue: $4.0M (vs $6.7M YoY) 🔹 Gross Margin: 50.8% (vs 47.2% YoY) 🟢 🔹 G&A Expense: $4.0M (slightly down) 🔹 Net Loss: $(3.4M) or $(0.11)/share (vs net income last year) 🔹 Cash: $11.7M (vs $15.4M at year-end) 👉 Core takeaway: Revenue decline expected as BARDA base phase winds down, but gross margin improved and development work advances 📈 GROWTH ENGINE (CORE STORY) 🟢 DeepView® System for burn wound healing assessment 🟢 AI-powered medical diagnostics platform 🟢 Focus on faster, more accurate treatment decisions in wound care 👉 This is: AI-driven predictive diagnostics company targeting burn and wound care markets --- 🚀 STRATEGIC MOVES 🟢 $31.7M BARDA funding supporting DeepView burn indication development 🟢 FDA De Novo 510(k) submission made in June 2025 🟢 Strengthened leadership with return of CFO David McGuire 👉 This is: Non-dilutive funding regulatory progress toward commercialization --- ⚡ WHAT’S HAPPENING? • Revenue reflects anticipated BARDA phase transition • Continued investment in DeepView System development • Gross margin expansion on direct labor mix • Cash runway supported by BARDA contract --- 📉 PROFITABILITY 🔹 GAAP Net Loss driven partly by warrant liability changes 🔹 Operating expenses well controlled 👉 Translation: Typical development-stage biotech profile with non-cash items impacting GAAP results --- 📅 2026 GUIDANCE 🔹 Revenue: Approximately $18.5M (primarily BARDA-related) --- 🧠 WHAT’S ACTUALLY WORKING 🟢 Improved gross margin 🟢 Non-dilutive BARDA funding accelerating development 🟢 FDA submission completed 🟢 Strong leadership reinforcement --- ⚠️ WEAK SPOTS 🔻 Revenue decline as expected from BARDA phase transition 🔻 GAAP net loss 🔻 Cash decreased sequentially 🔻 Pre-commercial stage (no product revenue yet) 👉 Still: Early-stage AI medical diagnostics company --- 🧠 MARKET SIGNAL 👉 AI-powered wound diagnostics developer with major non-dilutive government support --- 🔥 BULL vs BEAR 🟢 Bull Case • FDA clearance for DeepView burn indication • Successful commercialization ramp • Additional BARDA or commercial contracts • AI platform expansion into broader wound care 🔴 Bear Case • Regulatory delays • Slower than expected commercialization • Continued cash burn • Competition in wound diagnostics space --- 💭 CONCLUSION $MDAI reported expected revenue decline as it transitions BARDA phases, but maintained solid gross margins and continues advancing its DeepView System with significant non-dilutive funding. 👀 KEY QUESTION Will Spectral AI secure FDA market authorization for DeepView and begin generating commercial revenue in the coming periods?

what all you review in deepview scans ? I do Highest volume liquid movers deepview leaders Bullish combo tight range